Hospital

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

This study validates the need for universal HBV therapy for hepatitis B infections among people coinfected with HIV.

The FDA expanded Casgevy’s indication to include children 2 years and older with sickle cell disease with recurrent VOCs or transfusion-dependent β-thalassemia, making it the first gene therapy approved for patients as young as 2 years with SCD.

By targeting aldosterone synthesis directly, baxdrostat offers a novel mechanism for addressing resistant hypertension.

The systems connecting care are proving just as important as the treatments themselves.

AZA Allsop, MD, PhD, outlines what REMS-style safety monitoring could look like for psychedelic therapies and why top institutions are investing heavily.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.

The NIH’s expanded All of Us data set links genomic, clinical, environmental, and wearable data from a diverse population to advance precision medicine and pharmacogenomic research.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

A systematic review of 23 randomized trials suggests melatonin may modestly reduce musculoskeletal pain and improve sleep, although pharmacists should emphasize uncertain dosing, supplement quality, and the need to use it only as an adjunct to individualized pain care.

Messenger RNA vaccines were effective against any documented SARS-CoV-2 infection, against hospitalization, and against mortality within 14 to 42 days of vaccination.

Guests Adrian Wong, PharmD, MPH, BCCCP; and Cayley Krkljes, PharmD, BCPS, about a systematic review of phenobarbital and primidone drug-drug interactions, highlighting clinically significant risks when used with other therapies.

The POSEIDON clinical trial shows that high-sensitivity C-reactive protein levels remain elevated in approximately 2 in 5 patients with CVD, pointing to a gap in residual inflammatory risk management.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on why effective opioid stewardship in acute pain care must extend beyond prescription reduction to include multimodal analgesia, patient-centered outcomes, and standardized health-system pathways.

A randomized clinical trial found that both family-based therapy and individual psychoeducational motivational therapy improved symptoms of avoidant/restrictive food intake disorder.

Recent research and drug developments are reshaping clinical practice.

Yale's AZA Allsop, MD, PhD, on psychedelics as medicine vs wellness tools, and why naturalistic research settings matter for the field.

Tregzi is indicated in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen for hematopoietic and immunologic reconstitution and to improve chronic graft-vs-host disease–free survival.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how multimodal, individualized care can improve acute pain management for opioid-tolerant patients and those receiving buprenorphine or methadone.

Findings from EPCORE DLBCL-4 show that fixed-duration epcoritamab plus lenalidomide significantly improved progression-free survival (PFS) vs R-GemOx in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Pharmacist-led MTM services can deliver measurable clinical and financial value while advancing patient-centered care.

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

PCOS becomes PMOS, spotlighting metabolic and endocrine risks.

A combination regimen of azacitidine, venetoclax, and gilteritinib shows encouraging benefits in patients with newly diagnosed FLT3-mutated AML who were ineligible for intensive chemotherapy.

In an interview with Pharmacy Times, Caitlin Jones, PhD, discusses why high-risk, low-benefit treatments for chronic low back pain require greater scrutiny.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.